- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
McKesson Corporation $MCK Shares Sold by Pitcairn Co.
Institutional investor reduces stake in pharmaceutical distribution giant
Published on Mar. 8, 2026
Got story updates? Submit your updates here. ›
Pitcairn Co., an investment management firm, has reduced its position in McKesson Corporation (NYSE:MCK) by 59.1% during the third quarter, according to a recent SEC filing. The fund now owns 903 shares of the company's stock, down from 2,207 shares previously.
Why it matters
McKesson is one of the largest pharmaceutical distributors in the United States, playing a crucial role in the healthcare supply chain. Changes in institutional ownership can signal shifts in investor sentiment and market expectations around the company.
The details
Pitcairn Co. sold 1,304 shares of McKesson during the third quarter, reducing its total stake in the company to 903 shares. The remaining shares were valued at $698,000 as of the most recent SEC filing. Several other institutional investors also made changes to their McKesson holdings during the quarter, with some adding to their positions and others, like Pitcairn, reducing their exposure.
- Pitcairn Co. filed its most recent 13F report with the SEC on September 30, 2026, disclosing the reduced McKesson position.
The players
Pitcairn Co.
An investment management firm that has reduced its stake in McKesson Corporation.
McKesson Corporation
A global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions.
The takeaway
The reduction in Pitcairn Co.'s McKesson position suggests a potential shift in investor sentiment around the pharmaceutical distributor, though the overall institutional ownership remains high at 85.07%. Analysts continue to maintain a Moderate Buy rating on the stock, with a focus on the company's role in the healthcare supply chain and its financial performance.
